<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03546803</url>
  </required_header>
  <id_info>
    <org_study_id>17-006813</org_study_id>
    <secondary_id>ROR1603</secondary_id>
    <nct_id>NCT03546803</nct_id>
  </id_info>
  <brief_title>3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis</brief_title>
  <official_title>Assessment of 3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study observes a liquid skin protectant that is a polymeric-cyanoacrylate solution
      designed to protect intact or damaged skin due to radiation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Actual">August 12, 2019</completion_date>
  <primary_completion_date type="Actual">August 12, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>compare radiation dermatitis severity</measure>
    <time_frame>3 months (+/- 1 month) following the completion of radiation therapy</time_frame>
    <description>To compare radiation dermatitis severity in irradiated skin protected by a liquid skin protectant (3M™ Cavilon™ Advanced Skin Protectant) that rapidly dries versus uncovered skin (internal control) as determined by a panel.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Radiation Dermatitis</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Head and Neck Patients; Photon or Proton Treatment with product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Hair/skin fold areas (Axilla, Groin, Perineum); Photon or Proton Treatment with product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <description>Misc. (per Rad Onc Physician); Photon or Proton Therapy with routine skin care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3M™ Cavilon™ Advanced Skin Protectant</intervention_name>
    <description>liquid skin protectant on skin to protect from radiation dermatitis</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Radiation therapy patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18years.

          -  Patient has initial or recurrent disease

          -  Undergoing external beam radiotherapy at the Mayo Clinic Rochester campus Note:
             Patients who are undergoing concurrent chemotherapy are eligible

          -  Ability to complete questionnaire(s) by themselves or with assistance

          -  Provide informed written consent

          -  Willing to consent for photography of radiation field

          -  Available to return to Mayo Clinic in within 1 week post treatment for assessment (+/-
             7 days).

          -  At risk for developing ≥ grade 2 dermatitis radiation as determined by treating
             Radiation Oncology clinician

          -  Biologic effective dose of &gt;42 Gy10 as calculated using the web site EQD2.com.

        Exclusion Criteria:

          -  Unable to provide informed consent

          -  Patients with active rash, pre-existing dermatitis, lupus or scleroderma within the
             treatment area that may make skin assessment for the study difficult

          -  Known history of developing an allergic reaction after using a product containing
             cyanoacrylate or acrylates

          -  Subject has a medical condition that in the opinion of the investigator should exclude
             him/her from participating in the study

          -  Subject has been enrolled in an investigational study where product was applied to the
             proposed study site within 30 days of the screening visit

          -  The skin area affected by radiation requires treatment with a concomitant medication
             or product (if applicable)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ivy A. Petersen, M.D.</investigator_full_name>
    <investigator_title>Radiation Oncology Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

